View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
February 22, 2019updated 28 Mar 2022 9:03am

MS is more prevalent in the US than previously reported

10-year multiple sclerosis prevalent cases in the US are almost twice as high as previously reported cases.

By GlobalData Healthcare

The prevalence of multiple sclerosis (MS) in the US is nearly double previous estimates.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

MS is a chronic auto-immune disease that is usually diagnosed in younger adults, typically between ages 15–60 years.

In 2016, GlobalData estimated that the US had around 400,000 diagnosed prevalent cases.

However, new data from a study conducted by Mitchell T Wallin et al (and supported by the US National MS Society) found that 10-year MS prevalent cases in the US are almost twice as high as previously reported cases, at an estimated 727,344 people in 2017.

MS estimates for the US

The new MS estimates for the US was published in the journal Neurology in February 2019.

This study mitigated several data limitations in our current understanding of MS in the US. First, the study extracted patient claims data from six healthcare systems in the US (Optum, Truven Health Market Scan, Kaiser Permanente Southern California, Department of Veterans Affairs, Medicaid and Medicare) in order to mitigate the lack of a centralised medical record system in the US.

Second, due to the chronic relapsing nature of MS, many patients in the US could go years without being seen by a doctor and thus are not counted in short-term medical record-based epidemiological studies. This study accounted for the underestimation by analysing data over a three-year period and projecting to 10-year prevalence.

This new estimate put US MS prevalence at around 0.3% of the general population, which is on par with that of Canada and other Northern European markets.

The implications of this new finding include that the MS burden in the US is much higher than previously thought and that MS patients in the US may not be getting adequate care. Since MS is a disease that gets worse over time, regular doctor visits are essential even if the patient is not on disease-altering treatments.

MS prevalence estimates in the 16MM, compared with new US data

Source: GlobalData Notes: 16MM = Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Russia, South Africa, South Korea, Spain, the UK and the US.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management